MENU
Logo Made in Germany BIO 2018

PAION AG

Booth number: 1501-5

www.paion.com
info@paion.com

About us

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in the final stage of clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its development program in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. In the EU, PAION is currently planning to continue the clinical development program by starting a Phase III trial in the second half of 2018. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam.

PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia.



Products and services

Remimazolam is an ultra-short-acting intravenous benzodiazepine sedative/anesthetic that has already shown positive results in clinical Phase III trials. Data so far indicate that remimazolam has a rapid onset and offset of action combined with a favorable cardio-respiratory safety profile.

Remimazolam is in the final stage of clinical development for procedural sedation in the U.S. Currently, an integrated overall analysis of all clinical studies with remimazolam is being conducted in preparation of Cosmo’s filing for market approval. After completion of the development for procedural sedation, Cosmo will be responsible for any further development activities in the U.S. A full clinical development program for general anest¬hesia was completed in Japan. In Europe, it is planned to start a Phase III study in general anesthesia in the second half of 2018.


Remimazolam is partnered in the U.S., Canada, China, Russia (CIS), Turkey, the MENA region, South Korea and Japan.

Contacts

Address
PAION AG
Martinstr. 10—12
52062 Aachen
Germany

Phone: +49 241 4453-152

Ralf Penner
VP Investor Relations/Public Relations
Phone: +49 160 97723812
r.penner@paion.com


Business matching
Get in contact with German companies in 3 easy steps! With one single question you can reach all relevant German Pavilion exhibitors of your selected industrial branch.

Click here if you notice an image that violates copyright or privacy rights.

Your personal organizer

Your personal organizer

Print list  |  Save as PDF
This is your personal organizer to manage your contacts to the German exhibitors.